New depression drug SPT-300 enters Mid-Stage trial
Symptom relief
Recruiting now
This study tests a new drug called SPT-300 in 360 adults with major depression, with or without anxiety. Participants will receive either the drug or a placebo for 42 days to see if it reduces depression symptoms. The goal is to find a safe and effective new treatment option.
Phase: PHASE2 • Sponsor: Seaport Therapeutics • Aim: Symptom relief
Last updated May 03, 2026 09:52 UTC